| Literature DB >> 26841913 |
Abstract
BACKGROUND: Chronic haemodialysis for adult patients with end-stage kidney failure requires a patent extracorporeal circuit, maintained by anticoagulants such as unfractionated heparin (UFH). Incorrect administration of UFH has safety implications for patients.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26841913 PMCID: PMC6091600 DOI: 10.4102/curationis.v38i1.1447
Source DB: PubMed Journal: Curationis ISSN: 0379-8577
Dialysis units included in the study.
| Information categories | Dialysis institutions/Administration body | ||||||
|---|---|---|---|---|---|---|---|
| Public | Private | ||||||
| Centre 1 | Centre 2 | Centre 3 | Centre 4 | Centre 5 | Centre 6 | Centre 7 | |
| Number of dialysis units | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Classification | Tertiary | Tertiary | n/a | n/a | n/a | n/a | n/a |
| Registered nurses | 8 (38.1%) | 17 58.6) | 8 (66.7) | 10 (76.9) | 14 (73.7) | 4 (100) | 5 (83.3) |
| Enrolled nurses | 5 (23.8%) | 5 (17.2) | 1 (8.3) | 1 (7.7) | 2 (10.5) | - | 1 (16.7) |
| Clinical technologists | 8 (38.1) | 7 (24.1) | 3 (25) | 2 (15.4) | 3 (15.8) | - | - |
Number of dialysis units included in study: n = 7. n/a, not applicable.
Respondents’ self-reported knowledge results by professional category.
| Questions and responses | Professional category ( | ||
|---|---|---|---|
| RN ( | CT ( | EN ( | |
| Yes | 51 (100.0) | 19 (90.5) | 5 (100.0) |
| No | 0 (0.0) | 1 (4.8) | 0 (0.0) |
| Missing | 0 (0.0) | 1 (4.8) | 0 (0.0) |
| Total | 51 (100.0) | 21 (100.0) | 5 (100.0) |
| Yes | 25 (49.0) | 4 (19.0) | 1 (20.0) |
| No | 25 (49.0) | 16 (76.2) | 3 (60.0) |
| Unsure | 0 (0.0) | 1 (4.8) | 1 (20.0) |
| Missing | 1 (2.0) | 0 (0.0) | 0 (0.0) |
| Total | 51 (100.0) | 21 (100.0) | 5 (100.0) |
| Bleeding | 22 (43.1) | 11 (52.4) | 3 (60.0) |
| Nil ill effects | 12 (23.5) | 1 (4.8) | 0 (0.0) |
| Bleeding and unscheduled hospitalisation | 16 (31.4) | 8 (38.1) | 0 (0.0) |
| Missing | 1 (2.0) | 1 (4.8) | 2 (40.0) |
| Total | 51 (100.0) | 21 (100.0) | 5 (100.0) |
| Yes | 5 (9.8) | 1 (4.8) | 1 (20.0) |
| No | 42 (82.4) | 17 (81.0) | 3 (60.0) |
| Unsure | 4 (7.8) | 1 (4.8) | 0 (0.0) |
| Missing | 0 (0.0) | 2 (9.5) | 1 (20.0) |
| Total | 51 (100.0) | 21 (100.0) | 5 (100.0) |
| 420-450 x 109/1 | 4 (7.8) | 0 (0.0) | 0 (0.0) |
| 50-80 x 109/1 | 41 (80.4) | 15 (71.4) | 4 (80.0) |
| 150-180 x 109/1 | 4 (7.8) | 3 (14.3) | 0 (0.0) |
| Missing | 2 (3.9) | 3 (14.3) | 1 (20.0) |
| Total | 51 (100.0) | 21 (100.0) | 5 (100.0) |
| PS 1 mg/100 IU UFH | 23 (45.1) | 5 (23.8) | 1 (20.0) |
| PS 2 mg/1000 IU UFH | 10 (19.6) | 8 (38.1) | 3 (60.0) |
| Vitamin K 1 mg | 9 (17.6) | 1 (4.8) | 0 (0.0) |
| Unsure | 9 (17.6) | 6 (28.6) | 0 (0.0) |
| Missing | 0 (0.0) | 1 (4.8) | 1 (20.0) |
| Total | 51 (100.0) | 21 (100.0) | 5 (100.0) |
| Effectiveness | 4 (7.8) | 0 (0.0) | 0 (0.0) |
| Effects | 23 (45.1) | 9 (42.9) | 2 (40.0) |
| Pharmacokinetics | 9 (17.6) | 1 (4.8) | 0 (0.0) |
| Destroyed by stomach acids | 10 (19.6) | 8 (38.1) | 0 (0.0) |
| Unsure | 1 (2.0) | 1 (4.8) | 0 (0.0) |
| Missing | 4 (7.8) | 2 (9.5) | 3 (60.0) |
| Total | 51 (100.0) | 21 (100.0) | 5 (100.0) |
| Bleeding risk | 31 (60.8) | 12 (57.1) | 1 (20.0) |
| Increased urea levels | 1 (2.0) | 0 (0.0) | 1 (20.0) |
| Risk of complications | 4 (7.8) | 3 (14.3) | 0 (0.0) |
| Unsure | 4 (7.8) | 1 (4.8) | 0 (0.0) |
| Dosage | 1 (2.0) | 0 (0.0) | 0 (0.0) |
| Information | 1 (2.0) | 0 (0.0) | 0.(0.0) |
| Missing | 9 (17.6) | 5 (23.8) | 3 (60.0) |
| Total | 51 (100.0) | 21 (100.0) | 5 (100.0) |
| Intravenously | 37 (72.5) | 11 (52.3) | 5 (100.0) |
| Via dialysis machine | 13 (25.5) | 7 (33.3) | 3 (60.0) |
| Bolus dosage | 1 (2.0) | 2 (9.5) | 0 (0.0) |
| Missing | 0 (0.0) | 1 (4.8) | |
| Total | 51 (100.0) | 21 (100.0) | 2 (40.0) |
| Porcine | 20 (39.2) | 7 (33.3) | 1 (20.0) |
| Bovine | 10 (19.6) | 6 (28.6) | 0 (0.0) |
| Other | 10 (19.6) | 0 (0.0) | 2 (40.0) |
| Unsure | 8 (15.7) | 6 (28.6) | 0 (0.0) |
| Missing | 3 (5.9) | 2 (9.5) | 2 (40.0) |
| Total | 51 (100.0) | 21 (100.0) | 5 (100.0) |
| Patient temp | 1 (2.0) | 0 (0.0) | 0 (0.0) |
| < 25 degrees C | 32 (62.7) | 18 (85.7) | 2 (40.0) |
| > 25 degrees C | 6 (11.8) | 1 (4.8) | 0 (0.0) |
| Room temp | 6 (11.8) | 1 (4.8) | 2 (40.0) |
| Missing | 6 (11.8) | 1 (4.8) | 1 (20.0) |
| Total | 51 (100.0) | 21 (100.0) | 5 (100.0) |
| Hyperkalemia | 22 (43.1) | 8 (38.1) | 2 (40.0) |
| Nil | 9 (17.6) | 1 (4.8) | 2 (40.0) |
| Don’t know | 8 (15.7) | 5 (23.8) | 0 (0.0) |
| Inhibit the secretion of aldosterone-hyperkalemia | 3 (5.9) | 2 (9.5) | 0 (0.0) |
| Missing | 9 (17.6) | 5 (23.8) | 1 (20.0) |
| Total | 51 (100.0) | 21 (100.0) | 5 (100.0) |
| 10 mL | 32 (62.7) | 15 (71.4) | 0 (0.0) |
| 2000 IU | 0 (0.0) | 2 (9.5) | 0 (0.0) |
| 10 ML- 100 IU | 0 (0.0) | 1 (4.8) | 0 (0.0) |
| 01-5 mL | 5 (9.8) | 0 (0.0) | 0 (0.0) |
| 10-100 | 5 (9.8) | 0 (0.0) | 1 (20.0) |
| 1000 IU | 3 (5.9) | 0 (0.0) | 0 (0.0) |
| 10 000 IU | 1 (2.0) | 0 (0.0) | 0 (0.0) |
| Formula only | 2 (3.9) | 0 (0.0) | 1 (20.0) |
| Missing | 3 (5.9) | 3 (14.3) | 3 (60.0) |
| Total | 51 (100.0) | 21 (100.0) | 5 (100.0) |
Demographics of respondents.
| Variables | Professional Category | ||
|---|---|---|---|
| RN - | CT - | EN - | |
| 21-30 | 5 (9.8) | 10 (47.6) | 0 (0.0) |
| 31-40 | 10 (19.6) | 8 (38.1) | 1 (20.0) |
| 41-50 | 19 (37.3) | 2 (9.5) | 4 (80.0) |
| 51-60 | 12 (23.5) | 1 (4.8) | 0 (0.0) |
| > 61 | 2 (3.9) | 0 (0.0) | 0 (0.0) |
| Missing | 3 (5.9) | 0 (0.0) | 0 (0.0) |
| Subtotal | 48 (94.1) | 21 (100.0) | 5 (100.0) |
| Total | 51 (100.0) | 21 (100.0) | 5 (100.0) |
| Male | 6 (11.8) | 13 (61.9) | 0 (0.0) |
| Female | 45 (88.2) | 8 (38.1) | 5 (100.0) |
| Total | 51 (100.0) | 21 (100.0) | 5 (100) |
| South Africa | 48 (94.1) | 20 (95.2) | 5 (100.0) |
| Other | 2 (3.9) | 1 (4.8) | 0 (0.0) |
| Missing | 1 (2.0) | 0 (0.0) | 0 (0.0) |
| Subtotal | 50 (98.0) | 21 (100.0) | 5 (100.0) |
| Total | 51 (100.0) | 21 (100.0) | 5 (100.0) |
| PGDNN | 7 (13.7) | 0 (0.0) | 0 (0.0) |
| Dip CC | 8 (15.7) | 0 (0.0) | 0 (0.0) |
| Dip Nephro CT | 0 (0.0) | 11 (52.4) | 0 (0.0) |
| B Tech Nephro CT | 0 (0.0) | 8 (38.1) | 0 (0.0) |
| OJT | 27 (52.9) | 0 (0.0) | 5 (100.0) |
| PGDNN+Dip CC | 2 (3.9) | 0 (0.0) | 0 (0.0) |
| Dip CC+OJT | 6 (11.8) | 0 (0.0) | 0 (0.0) |
| Dip Nephro CT + B Tech Nephro CT | 0 (0.0) | 1 (4.8) | 0 (0.0) |
| Dip Nephro CT + OJT | 0 (0.0) | 1 (4.8) | 0 (0.0) |
| PGDNN+Dip CC + OJT | 1 (2.0) | 0 (0.0) | 0 (0.0) |
| Total | 51 (100.0) | 21 (100.0) | 5 (100.0) |
| 0-5 | 29 (56.9) | 10 (47.6) | 2 (40.0) |
| 6-40 | 22 (43.1) | 11 (52.4) | 3 (60.0) |
| Total | 51 (100.0) | 21 (100.0) | 5 (100.0) |
| Yes | 35 (68.6) | 17 (81.0) | 2 (40.0) |
| No | 16 (31.4) | 4 (19.0) | 2 (40.0) |
| Missing | 0 (0.0) | 0 (0.0) | 1 (20.0) |
| Subtotal | 51 (100.0) | 21 (100.0) | 4 (80.0) |
| Total | 51 (100.0) | 21 (100.0) | 5 (100.0) |
| On orientation | 1 (2.0) | 0 (0.0) | 0 (0.0) |
| Days | 0 (0.0) | 1 (4.8) | 0 (0.0) |
| Weeks | 14 (27.5) | 6 (28.6) | 5 (100.0) |
| Months | 22 (43.1) | 8 (38.1) | 0 (0.0) |
| Not Applicable | 14 (27.5) | 6 (28.6) | 0 (0.0) |
| Total | 51 (100.1) | 21 (100.1) | 5 (100.0) |
| Yes | 13 (25.5) | 11 (52.4) | 5 (100.0) |
| No | 37 (72.5) | 10 (47.6) | 0 (0.0) |
| Missing | 1 (2.0) | 0 (0.0) | 0 (0.0) |
| Subtotal | 50 (98.0) | 21 (100.0) | 5 (100.0) |
| Total | 51 (100.0) | 21 (100.0) | 5 (100.00 |
*, denotes missing data.
BTech Nephro CT, bachelor in technology (nephrology); CT=clinical technologist; Dip CC, diploma in critical care; Dip Nephro CT, diploma in clinical technology nephrology); EN, enrolled nurse; OJT, on job training; PGDNN, postgraduate diploma in nephrology nursing; RN, registered nurse; UFH, unfractionated heparin.
Overall KAP scores.
| KAP scores | Number of respondents | Minimum score | Maximum score | Mean score | SD |
|---|---|---|---|---|---|
| Knowledge scores (out of 18) | 77 | 4 | 18 | 10.8 | 3.1 |
| Attitudes scores (out of 41) | 77 | 0 | 35 | 25.9 | 6 |
| Practice scores (out of 50) | 77 | 19 | 44 | 35.8 | 6 |
KAP, knowledge, attitudes and practice; SD, standard deviation.
Association between knowledge and selected independent variables.
| Independent Variables | Knowledge | Fisher's exact test | |
|---|---|---|---|
| Acceptable number (%) | Poor number (%) | ||
| RN ( | 42 (72.4) | 9 (47.4) | 0.011 |
| CT ( | 15 (25.9) | 6 (31.6) | |
| EN ( | 1 (20.0) | 4 (80.0) | |
| 0-5 ( | 32 (55.2) | 9 (47.4) | 0.604 |
| 6-40 ( | 26 (44.8) | 10 (52.7) | |
| On orientation ( | 0 (0.0) | 1 (5.3) | 0.549 |
| Days ( | 1 (1.7) | 0 (0.0) | |
| Weeks ( | 20 (34.5) | 5 (26.3) | |
| Months ( | 22 (37.9) | 8 (42.1) | |
| Not applicable ( | 15 (25.9) | 5 (26.3) | |
| Yes ( | 19 (32.8) | 10 (55.6) | 0.101 |
| No ( | 39 (67.2) | 8 (44.4) | |
CT, clinical technologist; EN, enrolled nurse; RN, registered nurse; UFH, unfractionated heparin.
*, Adjustment of years of experience by knowledge both as continuous variables gave a Spearman's rho correlation of 0.571.
Association between attitude and selected independent variables.
| Independent Variables | Attitude | Fisher's exact test | |
|---|---|---|---|
| Positive number (%) | Negative number (%) | ||
| RN ( | 38 (69.1) | 13 (59.1) | 0.637 |
| CT ( | 14 (25.5) | 7 (31.8) | |
| EN ( | 3 (5.5) | 2 (9.1) | |
| 0-5 ( | 27 (49.1) | 14 (63.6) | 0.315 |
| 6-40 ( | 28 (50.9) | 8 (36.4) | |
| On orientation ( | 0 (0.0) | 1 (4.5) | 0.119 |
| Days ( | 0 (0.0) | 1 (4.5) | |
| Weeks ( | 17 (30.9) | 8 (36.4) | |
| Months ( | 21 (38.2) | 9 (40.9) | |
| Not Applicable ( | 17 (30.9) | 3 (13.6) | |
| Yes ( | 20 (37.0) | 9 (40.9) | 0.798 |
| No ( | 34 (63.0) | 13 (59.1) | |
CT, clinical technologist; EN, enrolled nurse; RN, registered nurse; UFH, unfractionated heparin.
*, Adjustment of years of experience by attitude, both as continuous variables gave a Spearman's rho correlation of 0.254.
Association between practice and selected independent variables.
| Independent Variables | Practice | Fisher's exact test | |
|---|---|---|---|
| Acceptable number (%) | Unacceptable number (%) | ||
| RN ( | 38 (65.5) | 13 (68.4) | 0.517 |
| CT ( | 15 (25.9) | 6 (31.6) | |
| EN ( | 5 (8.6) | 0 (0.0) | |
| 0-5 ( | 26 (44.8) | 15 (78.9) | 0.016 |
| 6-40 ( | 32 (55.2) | 4 (21.1) | |
| On orientation ( | 0 (0.0) | 1 (5.3) | 0.601 |
| Days ( | 1 (1.7) | 0 (0.0) | |
| Weeks ( | 19 (32.8) | 6 (31.6) | |
| Months ( | 23 (39.7) | 7 (36.8) | |
| Not applicable ( | 15 (25.9) | 5 (26.3) | |
| Yes ( | 26 (45.6) | 3 (15.8) | 0.028 |
| No ( | 31 (54.4) | 16 (84.2) | |
CT, clinical technologist; EN, enrolled nurse; RN, registered nurse; UFH, unfractionated heparin.
*, Adjustment of years of experience by practice, both as continuous variables gave a Spearman's rho correlation of 0.009.